What is your treatment approach for patients with an IDH wild-type, low-grade glioma?

Given the poor prognosis of molecular subtype, do you offer a more aggressive treatment regimen than for other molecular subtypes of low-grade glioma?

2 Answers

Mednet MemberInvited Expert

Radiation Oncology · University of Texas MD Anderson Cancer Center

Answered on

Our neuro-oncology group has begun using concurrent and adjuvant TMZ for patients with IDH wildtype. Our radonc group supports doses of 54 to 60Gy, favoring use of 60Gy on institutional protocol in order to assess the long-term outcomes.

Join for free or sign in to see the full answer

Mednet Member

Radiation Oncology · Mountain Radiation Oncology

Answered on

Timely ASCO abstract from NRG/RTOG 9802:

http://abstracts.asco.org/239/AbstView_239_252343.html

Wild type did not seem to benefit from PCV, but TMZ not evaluated.

Join for free or sign in to see the full answer